Last reviewed · How we verify
AGEN1884
At a glance
| Generic name | AGEN1884 |
|---|---|
| Also known as | Anti-CTLA-4, anti-CTLA-4 antibody |
| Sponsor | Agenus Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer (PHASE2)
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (PHASE2)
- Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy (PHASE1, PHASE2)
- AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer (PHASE2)
- Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) (PHASE1, PHASE2)
- AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma (PHASE2)
- Study of AGEN1884 With Pembrolizumab in 1L NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGEN1884 CI brief — competitive landscape report
- AGEN1884 updates RSS · CI watch RSS
- Agenus Inc. portfolio CI